RESPONSE GENETICS............

buran und MfG  

:::::::::::::::: 1,47 € +0,48% +0,007 € ,GrB
 

Datum Erster Hoch Tief Schluss     Stücke Volumen
24.10.13 2,07 2,15 2,01  2,09 $ 16.077 32.607

GrB  

Berlin 1,557  Nasdaq 2,14 $  buran und MfG und tau
 

Zeit  Kurs  Stück  
20:20:56 2,08 $  100  
20:08:22 2,08 $  100  
19:59:28 2,08 $  100  
19:59:25 2,07 $  100  
19:59:25 2,0799 $  1.500  
19:59:25 2,08 $  1.500  
19:57:42 2,08 $  1.400  
19:57:41 2,08 $  100  
19:57:11 2,07 $  650  
19:17:35 2,08 $  200  
19:17:35 2,09 $  300  
19:17:35 2,07 $  100  
19:17:35 2,09 $  300  
17:31:24 2,0801 $  1.900  
17:31:24 2,08 $  100  
17:30:52 2,091 $  2.500  
16:40:01 2,06 $  400  
16:40:01 2,061 $  1.600  
16:27:21 2,041 $  300  
16:20:59 2,031 $  100  
16:20:59 2,04 $  100

Kosmonova buran  

Zeit
                Kurs               Stück                    §
  21:00:00§2,04 $
                 318                    §
  20:59:54§2,04 $
                 100                    §
  20:59:53§2,01 $
                 100                    §
  20:55:06§2,0111 $
                 100                    §
  20:50:34§2,03 $
                 600                    §
  20:50:13§2,02 $
          §1.000
  20:50:07§2,021 $
               1.100                    §
  20:50:07§2,02 $
                 100                    §
  20:50:07§2,021 $
                 100                    §
  20:50:06§2,02 $
               1.300                    §
  20:39:16§2,03 $
                 200                    §
  20:39:14§2,04 $
                 100                    §
  20:20:59§2,0375 $
                 100                    §
  19:53:01§2,05 $
               3.280                    §
  19:48:07§2,05 $
                 800                    §
  19:07:28§2,055 $
                 300                    §
  19:07:14§2,05 $
                 300                    §
  18:11:01§2,05 $
                 100                    §
  18:11:00§2,05 $
               5.743                    §
  18:10:49§2,0501 $
               1.992                    §
  18:08:28§2,06 $
                 100                    §
  18:08:21§2,06 $
                 100                    §
  18:07:35§2,10 $
                 500                    §
  17:53:09§2,05 $
                 100                    §
  17:52:14§2,05 $
                 200                    §
  17:52:00§2,05 $
                 100                    §
  17:51:20§2,05 $
                 200                    §
  17:48:45§2,079 $
               2.000                    §
  17:02:17§2,05 $
                 300                    §
  17:01:38§2,05 $
               3.010                    §
  16:59:44§2,05 $
                 100                    §
  16:42:12§2,06 $
                 100                    §
  16:40:58§2,06 $
                 200                    §
  16:40:29§2,07 $
               1.000                    §
  16:35:10§2,07 $
                 200                    §
  16:26:28§2,06 $
                 100                    §
  16:15:25§2,07 $
               1.000                    §
  15:53:51§2,07 $
                 100                    §
  15:44:29§2,13 $
                 300                    §
  15:15:03§2,0502 $
                 250                    §
  15:15:03§2,0501 $
                 200§
buran  

Zeit  Kurs  Stück  
15:22:24 2,0101 $  250  
15:19:00 2,0101 $  2.000  
14:48:47 2,02 $  1.000  
14:35:00 2,02 $  100

GrB  

::::::::::::::: 2,05 $ +0,49% +0,01 $ In Euro: 1,5201 € | Nasdaq ,GrB  

::::::::::::: 2,11 $ +3,43% +0,07 $ In Euro: 1,5641 € | Nasdaq, 01.11.13 ,GrB  

Zeit
                Kurs               Stück                    §
  15:58:21§2,20 $
                 100                    §
  15:50:08§2,20 $
                 100                    §
  15:47:24§2,149 $
                 250                    §
  15:47:24§2,15 $
                 500                    §
  15:47:23§2,149 $
                 500                    §
  15:47:22§2,18 $
                 100                    §
  15:31:43§2,1499 $
                 475                    §
  15:30:00§2,14 $
                 300§
GrB  

::::::::::::::: 2,14 $ +1,42% +0,03 $ In Euro: 1,5855 € | Nasdaq, 04.11.13 ,GrB  

RTK 1,546 € RTP +1,38 Pott +5,17% ,GrB  

Zeit   Kurs Stück
  15:30:12§2,0392 $ 475
  15:30:00§2,17 $ 100
___________________
GRATULATION  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  05.11.13      2,17      2,22§2,0392 2,09 $ 11.809 22.990

GrB  

in 1999 to leverage breakthrough, patented technology from USC for the extraction of genetic information from formalin-fixed, paraffin-embedded clinical trial samples. Until that time, it was not possible to extract meaningful genetic information from standard diagnostic specimens.

Our success in developing this technology allows us to deliver tangible benefits to physicians and pharmaceutical companies and to support the development of more personalized patient therapies in an efficient, cost-effective manner.
Our Mission

To provide timely, accurate, and validated diagnostic testing services to physicians and pharmaceutical companies that enable personalized cancer treatment.
Our Clients

Response Genetics has client relationships with some of the largest pharmaceutical companies in the world including:

GlaxoSmithKline

Roche

Taiho Pharmaceuticals
http://www.responsegenetics.com/about-us/corporate-overview/  

(NASDAQ:RGDX)  is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies which enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and is located in Los Angeles, California. For more information, please visit www.responsegenetics.com
http://investor.responsegenetics.com/  

Here you will find a summary of Response Genetics, Inc.'s latest financial information.
http://investor.responsegenetics.com/financials.cfm  

http://investor.responsegenetics.com/annual-proxy.cfm GrB  

Nov 7, 2013
10:00 AM ET Response Genetics, Inc. Third Quarter 2013 Financial Results Conference Call
http://investor.responsegenetics.com/events.cfm  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  06.11.13      2,12      2,19§2,00 2,03 $ 55.183 114 T

GrB  

http://investor.responsegenetics.com/events.cfm GrB  

October 2, 2013
Response Genetics, Inc. Announces Payor Contract With Fortified Provider Network

LOS ANGELES, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has executed an agreement with Fortified Provider Network, Inc. and will join its network of preferred providers. This latest agreement marks Response's seventh health care payor agreement this year and brings its access to over 97 million people nationally.

With the execution of this agreement, approximately 4.1 million members associated with over 200 health insurers, self-funded employers and other payors of health care services will be able to access Response Genetics' suite of molecular predictive testing at a discounted rate. Response Genetics' predictive genomic testing is targeted to patients battling lung, colon, gastric, and melanoma cancers. The results from Response Genetics' testing services give treating physicians actionable information that enable the best therapy to be employed on that specific patient's tumor. The precise nature of Response Genetics' services brings with them a value proposition that is expected to improve patient outcomes and enhance efficiencies in health care delivery.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

About Fortified Provider Network

Based in Scottsdale, Arizona, Fortified Provider Network (FPN) was founded in 1997 for the purpose of creating an all-direct-contracted network of preferred providers for its group health clients. Given FPN's superior results in the group health arena, FPN expanded over the years to offer workers' compensation and auto liability networks. FPN offers the utilization of its network to its payor clients and members who, in turn, are able to capitalize on the discounted fee schedules FPN has negotiated with its healthcare providers.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

CONTACT: Investor Relations Contact:

        Peter Rahmer

        Trout Group

        646-378-2973



        Company Contact:

        Thomas A. Bologna

        Chairman & Chief Executive Officer

        323-224-3900

Response Genetics Logo
Source: Response Genetics, Inc.

News Provided by Acquire Media
http://investor.responsegenetics.com/...sedetail.cfm?ReleaseID=794395
http://investor.responsegenetics.com/releases.cfm  

October 31, 2013
Response Genetics, Inc. to Release Third Quarter 2013 Financial Results and Host Conference Call on November 7, 2013

LOS ANGELES, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, will announce its third quarter 2013 financial results and give an operational update in a press release to be issued before the market opens on Thursday, November 7, 2013. The company will host a conference call that same day at 10:00 a.m. EST to discuss its financial results.

CONFERENCE CALL DETAILS

To access the conference call by phone on November 7 at 10:00 a.m. EST, dial (800) 537-0745 or (253) 237-1142 for international participants. A telephone replay will be available beginning approximately two hours after the call through November 9, 2013, and may be accessed by dialing (855) 859-2056 or (404) 537-3406. The conference passcode for both the live call and replay is 94263838.

To access the live and archived webcast of the conference call, go to the Investor Relations section of the Company's Web site at http://investor.responsegenetics.com/events.cfm.  It is advised that participants connect at least 15 minutes prior to the call to allow for any software downloads that might be necessary.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

CONTACT: Investor Relations Contact:

        Peter Rahmer

        Trout Group

        646-378-2973



        Company Contact:

        Thomas A. Bologna

        Chairman & Chief Executive Officer

        323-224-3900

Response Genetics Logo
Source: Response Genetics, Inc.

News Provided by Acquire Media
http://investor.responsegenetics.com/...sedetail.cfm?ReleaseID=803030
http://investor.responsegenetics.com/releases.cfm  

Response Genetics (NASDAQ: RGDX)

Last Price Change Open Day High 52-Week High
2.03
          §0.06  down   (2.871%) 2.12 2.19 2.93
Volume Previous Close Day Low 52-Week Low
55,200 2.09 2.00 0.99
http://investor.responsegenetics.com/stockquote.cfm  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  07.11.13      1,94      1,94§1,49 1,52 $ 319.573 0,51 M

GrB